Was ist bloß los mit Antisoma?
Hartkore_Diablo : Was ist bloß los mit Antisoma?
Kicky : das ist los
Shares of Antisoma , the British biopharmaceutical company focusing on cancer therapies, tumbled 15.1 percent to 160 pence on Wednesday after it said filing for approval for its ovarian cancer treatment pemtumomab would be delayed until 200.
Antisoma (LSE: ASM.L - news) said that following a meeting with the U.S. Food and Drug Administration on Tuesday, the regulator advised that the data from the Phase III study the treatment is currently undergoing should show stronger statistical evidence showing the drug's survival benefit over standard car.
As a result, Antisoma is increasing the number of patients recruited for the Phase III study to extend its research, leading to the delay in filing for any marketing approval.